USD 8.36
(2.96%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 568.19 Million USD | -29.25% |
2022 | 803.04 Million USD | 59.46% |
2021 | 503.61 Million USD | 145.54% |
2020 | 205.1 Million USD | 4.93% |
2019 | 195.46 Million USD | 0.0% |
2001 | 803.04 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 792.18 Million USD | 33.25% |
2024 Q1 | 594.49 Million USD | 4.63% |
2023 FY | 568.19 Million USD | -29.25% |
2023 Q4 | 568.19 Million USD | -26.56% |
2023 Q2 | 788.41 Million USD | -2.62% |
2023 Q1 | 809.62 Million USD | 0.82% |
2023 Q3 | 773.7 Million USD | -1.87% |
2022 Q4 | 803.04 Million USD | 86.34% |
2022 Q3 | 430.95 Million USD | 0.89% |
2022 Q2 | 427.16 Million USD | -3.72% |
2022 FY | 803.04 Million USD | 59.46% |
2022 Q1 | 443.67 Million USD | -11.9% |
2021 Q1 | 150.13 Million USD | -26.8% |
2021 FY | 503.61 Million USD | 145.54% |
2021 Q4 | 503.61 Million USD | -5.45% |
2021 Q3 | 532.62 Million USD | 108.91% |
2021 Q2 | 254.95 Million USD | 69.81% |
2020 FY | 205.1 Million USD | 4.93% |
2020 Q1 | - USD | 0.0% |
2020 Q4 | 205.1 Million USD | 0.0% |
2019 FY | 195.46 Million USD | 0.0% |
2001 FY | 803.04 Million USD | 0.0% |
2001 Q4 | 503.61 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ADC Therapeutics SA | 503.03 Million USD | -12.953% |
Alto Neuroscience, Inc. | 158.3 Million USD | -258.932% |
Annovis Bio, Inc. | 17.95 Million USD | -3063.798% |
Biohaven Pharmaceutical Holding Company Ltd. | 85.23 Million USD | -566.6% |
Nuvation Bio Inc. | 16.36 Million USD | -3372.62% |
Nuvation Bio Inc. | 16.36 Million USD | -3372.62% |
Arcus Biosciences, Inc. | 633 Million USD | 10.239% |
Zymeworks Inc. | 116.07 Million USD | -389.507% |